HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Additive effect of erythropoietin and heme on murine hematopoietic recovery after azidothymidine treatment.

Abstract
The ability of combination treatment with erythropoietin (Epo) and heme to rescue hematopoietic activity in mice from the suppressive effect of azidothymidine (AZT) was determined. Exposure of mice to AZT for 5 weeks produced marked anemia, thrombocytopenia, neutropenia, and weight loss, whereas mice that received Epo and heme for 3 subsequent weeks showed significant alleviation of AZT cytotoxicity. Treatment with Epo (10 U for 5 times/week) stimulated hematopoietic recovery in the AZT-treated animals and reduced the severe anemia and thrombocytopenia by 3 weeks. Administration of a lower Epo dose (1 U Epo) resulted in only a modest retardation of AZT-induced anemia, although, when combined with heme, there was a great improvement in recovery of erythropoiesis. The combination of heme with Epo (10 U) produced the optimum response, resulting in almost normal recovery of bone marrow cellularity as well as recovery of burst-forming units-erythroid (BFU-E) and splenic hematopoietic progenitor content (colony-forming unit-spleen [CFU-S]) by the end of 3 weeks of post-AZT treatment. Treatment with heme alone markedly enhanced the recovery of BFU-E and CFU-S, as well as body weight post-AZT; however, this recovery was not to the extent seen in combination with Epo (10 U). Long-term bone marrow cultures (LTBMCs) established from mice exposed to AZT for 8 weeks showed a marked reduction in cellularity and this was completely alleviated when mice received heme and Epo (10 U) for 3 weeks after 5 weeks of AZT administration. The additive effect of heme and Epo was seen in BFU-E production, as well as in CFU-S production, in LTBMCs. Thus, heme exerts a significant protective effect on hematopoietic progenitors in vivo and may be of potential clinical use in combination with Epo to promote effective erythropoiesis in the setting of AZT therapy.
AuthorsJ Harrison, A Kappas, R D Levere, J D Lutton, J L Chertkov, S Jiang, N G Abraham
JournalBlood (Blood) Vol. 82 Issue 12 Pg. 3574-9 (Dec 15 1993) ISSN: 0006-4971 [Print] United States
PMID8260696 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Erythropoietin
  • Heme
  • Zidovudine
Topics
  • Anemia (chemically induced)
  • Animals
  • Body Weight (drug effects)
  • Bone Marrow Cells
  • Cells, Cultured
  • Colony-Forming Units Assay
  • Drug Synergism
  • Erythropoietin (pharmacology)
  • Female
  • Hematopoiesis (drug effects)
  • Hematopoietic Stem Cells (cytology, drug effects)
  • Heme (pharmacology)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred DBA
  • Neutropenia (chemically induced)
  • Thrombocytopenia (chemically induced)
  • Weight Loss
  • Zidovudine (toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: